SCOPUS 정보 검색 플랫폼

Gynecologic Oncology

Volumn 81, Issue 1, 2001, Pages 1-2

Second-line therapy for potentially platinum-sensitive recurrent ovarian cancer: What is optimal treatment?

(1) Markman, Maurie a

a TAUSSIG CANCER INSTITUTE (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; EPIRUBICIN; PLATINUM DERIVATIVE;

CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG SENSITIVITY; EDITORIAL; FEMALE; GYNECOLOGIC CANCER; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT INDICATION;

EID: 0035056187 PISSN: 00908258 EISSN: None Source Type: Journal
DOI: 10.1006/gyno.2001.6162 Document Type: Editorial

Times cited : (10)

References (9)

1
- 0030054309
- Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
- (1996) N Engl J Med , vol.334 , pp. 1-6
- McGuire, W.P.¹ Hoskins, W.J.² Brady, M.F.³ Kucera, P.R.⁴ Partridge, E.E.⁵ Look, K.Y.⁶ Clarke-Pearson, D.L.⁷ Davidson, M.⁸

2
- 0034600305
- Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results
- (2000) J Natl Cancer Inst , vol.92 , pp. 699-708
- Piccart, M.J.¹ Bertelsen, K.² James, K.³ Cassidy, J.⁴ Mangioni, C.⁵ Simonsen, E.⁶ Stuart, G.⁷ Kaye, S.⁸ Vergote, I.⁹ Blom, R.¹⁰ Grimshaw, R.¹¹ Atkinson, R.J.¹² Swenerton, K.D.¹³ Trope, C.¹⁴ Nardi, M.¹⁵ Kaern, J.¹⁶ Tumolo, S.¹⁷ Timmers, P.¹⁸ Roy, J.-A.¹⁹ Lhoas, F.²⁰ more..

3
- 0033986363
- Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A Gynecologic Oncology Group study
- (2000) J Clin Oncol , vol.18 , pp. 106-115
- Muggia, F.M.¹ Braly, P.S.² Brady, M.F.³ Sutton, G.⁴ Niemann, T.H.⁵ Lentz, S.L.⁶ Alvarez, R.D.⁷ Kucera, P.R.⁸ Small, J.M.⁹

4
- 0035865144
- Phase III trial of standard dose intravenous cisplatin plus paclitaxel versus moderately high dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group
- (2001) J Clin Oncol , vol.19 , pp. 1001-1007
- Markman, M.¹ Bundy, B.N.² Alberts, D.S.³ Fowler, J.M.⁴ Clark-Pearson, D.J.⁵ Carson, L.F.⁶ Wadler, S.⁷ Sickel, J.⁸

5
- 0024589974
- Re-treatment of patients with recurrent epithelial ovarian cancer with cisplatin-based chemotherapy
- (1989) Obstet Gynecol , vol.73 , pp. 798-802
- Gershenson, D.M.¹ Kavanagh, J.J.² Copeland, L.J.³ Stringer, C.A.⁴ Morris, M.⁵ Wharton, J.T.⁶

6
- 0025103224
- Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds
- (1990) Gynecol Oncol , vol.36 , pp. 207-211
- Gore, M.E.¹ Fryatt, I.² Wiltshaw, E.³ Dawson, T.⁴

7
- 0000989020
- The "failure-free interval" defines the likelihood of resistance to carboplatin in patients with advanced epithelial ovarian cancer previously treated with cisplatin: Relevance to therapy and new drug testing
- (1991) Int J Gynecol Cancer , vol.1 , pp. 205-208
- Hoskins, P.J.¹ O'Reilly, S.E.² Swenerton, K.D.³

8
- 0026086870
- Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin
- (1991) J Clin Oncol , vol.9 , pp. 389-393
- Markman, M.¹ Rothman, R.² Hakes, T.³ Reichman, B.⁴ Hoskins, W.⁵ Rubin, S.⁶ Jones, W.⁷ Almadrones, L.⁸ Lewis J.L., Jr.⁹

9
- 0035056323
- Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer
- (2001) Gynecol Oncol , vol.81 , pp. 3-9
- Bolis, G.¹ Scarfone, G.² Giardina, G.³ Villa, A.⁴ Mangili, G.⁵ Melpignano, M.⁶ Presti, M.⁷ Tateo, S.⁸ Franchi, M.⁹ Parazzini, F.¹⁰

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.